Publicaciones (376) Publicaciones en las que ha participado algún/a investigador/a

2020

  1. A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population

    Journal of Adolescent Health, Vol. 67, Núm. 6, pp. 763-768

  2. A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus

    Molecular Pharmaceutics, Vol. 17, Núm. 5, pp. 1608-1620

  3. A Glimpse Behind the Hidden Curriculum

    Archivos de Bronconeumologia, Vol. 56, Núm. 7, pp. 418-419

  4. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  5. A Novel Cytotoxic Conjugate Derived from the Natural Product Podophyllotoxin as a Direct-Target Protein Dual Inhibitor

    Molecules, Vol. 25, Núm. 18

  6. A Trypanosoma cruzi Genome Tandem Repetitive Satellite DNA Sequence as a Molecular Marker for a LAMP Assay for Diagnosing Chagas' Disease

    Disease Markers, Vol. 2020

  7. A case of paraneoplastic cerebellar degeneration that preceded the diagnosis of classical Hodgkin’s lymphoma by 16 months

    American Journal of Case Reports, Vol. 21, pp. 1-5

  8. A case report of arterial and venous thromboembolism in a patient with severe COVID-19 pneumonia

    European Heart Journal - Case Reports, Vol. 4, Núm. 6

  9. A collection of three integration-free iPSCs derived from old male and female healthy subjects

    Stem Cell Research, Vol. 42

  10. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)

    Leukemia and Lymphoma, Vol. 61, Núm. 3, pp. 714-720

  11. A missense in HSF2BP causing primary ovarian insufficiency affects meiotic recombination by its novel interactor c19orf57/brme1

    eLife, Vol. 9, pp. 1-93

  12. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  13. A mutation in p62 protein (p. R321C), associated to Paget's disease of bone, causes a blockade of autophagy and an activation of NF-kB pathway

    Bone, Vol. 133

  14. A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia

    American Journal of Hematology, Vol. 95, Núm. 10, pp. 1214-1215

  15. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

    Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329

  16. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    Blood, Vol. 136, Núm. 21, pp. 2401-2409

  17. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 435-442

  18. A prognostic index predicting survival in transformed Waldenström macroglobulinemia

    Haematologica, Vol. Online ahead of print

  19. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

  20. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428